natgillin/translations-raw huggingface dataset:
A/California/7/2009 (H1N1)pdm09 - lignende stamme (A/California/7/2009, NYMC X-179A) ........
A/California/7/2009 (H1N1)pdm09 - like strain (A/California/7/2009, NYMC X-179A) .......
A/California/7/2009 (H1N1)pdm09-lignende stamme (A/Bolivia/559/2013, MEDI 255962) 107,0±0,5 FFU***
A/California/7/2009 (H1N1)pdm09 - like strain (A/Bolivia/559/2013, MEDI 255962) 107.0±0.5 FFU
A/California/7/2009 (H1N1)pdm09-lignende stamme (A/Brisbane/10/2010, vildtype) 15 mikrogram HA**
A/California/7/2009 (H1N1)pdm09 - like strain (A/Brisbane/10/2010, wild type) 15 micrograms HA
A/California/7/2009 (H1N1)pdm09-lignende stamme (A/California/7/2009, MEDI 228029) 107,0±0,5 FFU***
A/California/7/2009 (H1N1)pdm09-like strain (A/California/7/2009, MEDI 228029) 107.0±0.5 FFU
A/California/7/2009 (H1N1)pdm09-lignende stamme (A/California/7/2009, MEDI 228029) 107,0±0,5 FFU*** A/Victoria/361/2011 (H3N2)-lignende stamme (A/Texas/50/2012, MEDI 237514) 107,0±0,5 FFU*** B/Massachusetts/2/2012-lignende stamme (B/Massachusetts/2/2012, MEDI 237751) 107,0±0,5 FFU***
A/California/7/2009 (H1N1)pdm09-like strain (A/California/7/2009, MEDI 228029) 107.0±0.5 FFU*** A/Victoria/361/2011 (H3N2)-like strain (A/Texas/50/2012, MEDI 237514) 107.0±0.5 FFU*** B/Massachusetts/2/2012-like strain (B/Massachusetts/2/2012, MEDI 237751) 107.0±0.5 FFU
A/California/7/2009 (H1N1)psm09-lignende stamme (A/California/7/2009, MEDI 228029) 107,0±0,5 FFU***
A/California/7/2009 (H1N1)pdm09-like strain (A/California/7/2009, MEDI 228029) 107.0±0.5 FFU
A/California/7/2009 (H1N1)v-lignende stamme (X-179A) 3,75 mikrogram* AS03-adjuvans bestående af squalen, DL-α-tocopherol og polysorbat 80
A/California/7/2009 (H1N1)v-like strain (X-179A) 3.75 micrograms* AS03 adjuvant composed of squalene, DL--tocopherol and polysorbate 80
A/California/7/2009 (H1N1)v-lignende stamme (X-179A) i.m.
A/California/7/2009 (H1N1)v-like strain (X-179A) I.M.
A/Californien/7/2009 (H1N1)-lignende stamme (NYMC X-179A)...............................................30 µg**
A/California/7/2009 (H1N1)-like strain (NYMC X-179A)..............................................................30 µg
A/equine-2/Newmarket/2/93 50 AE
A/equine-2/ South Africa/4/03 50 AU1 A/equine-2/ Newmarket/2/93 50 AU
A/equine-2/Sydafrika/4/03 stamme 50AE/ml A/equine-2/Newmarket/2/93 stamme 50 AE/ml
A/equine-2/South Africa/4/03 strain 50 AU/ml A/equine-2/Newmarket/2/93 strain 50 AU/ml.
A/equine-2/Sydafrika/4/03 stamme 50AE/ml A/equine-2/Newmarket/2/93 stamme 50 AE/ml Tetanus toksoid ≥ 30 IE/ml
A/equine-2/South Africa/4/03 strain 50 AU/ml A/equine-2/Newmarket/2/93 strain 50 AU/ml Tetanus toxoid 40 Lf/ml
A/H5N1/Indonesia/5/2005-lignende stamme (PR8-IBCDC-RG2) 3,75 mikrogram** pr 0,5 ml dosis
A/H5N1/Indonesia/5/2005 like strain used (PR8-IBCDC-RG2)3.75 micrograms** per 0.5 ml dose
A/Hong Kong/4801/2014 (H3N2) - lignende stamme (A/Hong Kong/4801/2014, NYMC X-263B)
A/Hong Kong/4801/2014 (H3N2) - like strain (A/Hong Kong/4801/2014, NYMC X-263B)
A/Hong Kong/4801/2014 (H3N2)-lignende stamme (A/New Caledonia/71/2014, MEDI 263122) 107,0±0,5 FFU***
A/Hong Kong/4801/2014 (H3N2) - like strain (A/New Caledonia/71/2014, MEDI 263122) 107.0±0.5 FFU
A/Indonesia/05/2005
A/Indonesia/5/2005
A/Indonesia/05/2005 (H5N1)-lignende stamme (PR8-IBCDC-RG2) 3,75 mikrogram* AS03-adjuvans bestående af squalen, DL-α-tocopherol og polysorbat 80
A/Indonesia/05/2005 (H5N1) like strain used (PR8-IBCDC-RG2) 3.75 micrograms* AS03 adjuvant composed of squalene, DL--tocopherol and polysorbate 80
A/Indonesia/05/2005 (H5N1)-lignende stamme (PR8-IBCDC-RG2) 3,75 mikrogram**
A/Indonesia/05/2005 (H5N1) like strain used (PR8-IBCDC-RG2) 3.75 micrograms
A/Indonesia/5/2005 (H5N1)-lignende stamme (PR8-IBCDC-RG2) i.m.
A/Indonesia/5/2005 (H5N1) like strain used (PR8-IBCDC-RG2) I.M.
A/Switzerland/9715293/2013 (H3N2) -lignende stamme (A/South Australia/55/2014, vildtype) 15 mikrogram HA**
A/Switzerland/9715293/2013 (H3N2) - like strain (A/South Australia/55/2014, wild type) 15 micrograms HA
A/Switzerland/9715293/2013 (H3N2)-lignende stamme (A/South Australia/55/2014, vildtype) 15 mikrogram HA**
A/Switzerland/9715293/2013 (H3N2) - like strain (A/South Australia/55/2014, wild type) 15 micrograms HA
A/turkey/Turkey/1/05 (H5N1)-lignende stamme (NIBRG-23) 7,5 mikrogram hæmagglutinin
A/turkey/Turkey/1/05 (H5N1)-like strain (NIBRG-23) 7.5 micrograms haemagglutinin
A/Victoria/361/2011 (H3N2)-lignende stamme (A/Texas/50/2012, MEDI 237514) 107,0±0,5 FFU***
A/Victoria/361/2011 (H3N2)-like strain (A/Texas/50/2012, MEDI 237514) 107.0±0.5 FFU
A/Vietnam/1194/2004 (H5N1) 7,5 mikrogram hæmagglutinin
A/Vietnam/1194/2004 (H5N1) 7.5 micrograms haemagglutinin
A/Vietnam/1194/2004 (H5N1)-lignende stamme (NIBRG-14) 7,5 mikrogram hæmagglutinin
A/Vietnam/1194/2004 (H5N1)-like strain (NIBRG-14) 7.5 micrograms haemagglutinin
A/Vietnam/1203/2004 (H5N1)-stamme (A/Vietnam/1203/2004, MEDI 0141000136) 107,0±0,5 FFU
A/Vietnam/1203/2004 (H5N1) strain (A/Vietnam/1203/2004, MEDI 0141000136) 107.0±0.5 FFU
A/Vietnam/1203/2004 (H5N1)-stamme (A/Vietnam/1203/2004, MEDI 0141000136) 107,0±0,5 FFU***
A/Vietnam/1203/2004 (H5N1) strain (A/Vietnam/1203/2004, MEDI 0141000136) 107.0±0.5 FFU
a1 morgen, 2 aften b2 morgen, 2 aften
a1 morning, 2 evening b2 morning, 2 evening
A143P
C142W
A156D
D155H
A22 Iraq & SAT2 Saudi Arabia
A24 Cruzeiro and SAT2 Saudi Arabia
A22 Iraq and A24 Cruzeiro
O Taiwan 3/97 and Asia1 Shamir
A22 Iraq and A24 Cruzeiro and Asia1 Shamir
O Taiwan 3/97, A22 Iraq and Asia1 Shamir
A22 Iraq, A24
AFTOVAXPUR DOE
A24 Cruzeiro & SAT2 Saudi Arabia
A Turkey 14/98 and SAT2 Saudi Arabia
A24 Cruzeiro and A Turkey 14/98
A22 Iraq and A24 Cruzeiro
A24 Cruzeiro and A Turkey 14/98 and Asia1 Shamir
O Taiwan 3/97, A24 Cruzeiro and A Turkey 14/98
A24 Cruzeiro, A Turkey 14/98 & SAT2 Saudi Arabia
A24 Cruzeiro, A Turkey 14/98 and SAT2 Saudi Arabia
A24 Cruzeiro, Asia 1 Shamir & SAT2 Saudi Arabia
A24 Cruzeiro, Asia 1 Shamir and SAT2 Saudi Arabia
A309P
K308N
A352V
W349S
A5 arter (HPV 51)
A5 species (HPV 51)
A6 arter (HPV 56)
A6 species (HPV 56)
A73E
M72R
a90% konfidensinterval med mindre andet er angivet. b95% konfidensinterval.
a 90 % confidence intervals unless otherwise noted. b 95 % confidence intervals.
a90% konfidensinterval med mindre andet er angivet. b95% konfidensinterval.
a 90% confidence intervals unless otherwise noted. b 95% confidence intervals.
a: 1 dødeligt tilfælde b: 1 dødeligt tilfælde af pleural effusion forekom i MCL-forsøgets lavdosis-arm (175/25 mg)
a: one fatal case b: One pleural effusion fatal event occurred in the low-dose (175/25 mg) arm of the MCL study
a: 1 morgen, 2 aften b: 2 morgen, 2 aften
a: 1 morning, 2 evening b: 2 morning, 2 evening
a: 2 morgen, 2 aften
a: 2 morning, 2 evening
a: 25 mg Enbrel subkutant to gange om ugen b: p < 0,001, Enbrel vs. placebo c: p < 0,01, Enbrel vs. placebo
a: 25 mg Enbrel SC twice weekly b: p < 0.001, Enbrel vs. placebo c: p < 0.01, Enbrel vs. placebo
a: Behandling med konkomitant TMZ kan fortsættes, når alle de følgende betingelser er opfyldt: Absolut antal neutrofile ≥ 1,5 x 109/l; trombocyttal ≥ 100 x 109/l; CTC ikke- hæmatologisk toksicitet ≤ Grad 1 (undtagen for alopeci, kvalme, opkastning).
a: Treatment with concomitant TMZ can be continued when all of the following conditions are met: absolute neutrophil count ≥ 1.5 x 109/l; thrombocyte count ≥ 100 x 109/l; CTC non-haematological toxicity ≤ Grade 1 (except for alopecia, nausea, vomiting).
a: Behandling med konkomitant TMZ kan fortsættes, når alle de følgende betingelser er opfyldt: Absolut antal neutrofile ≥ 1,5 x 109/l; trombocyttal ≥ 100 x 109/l; CTC ikke-hæmatologisk toksicitet ≤ Grad 1 (undtagen for alopeci, kvalme, opkastning).
a: Treatment with concomitant TMZ can be continued when all of the following conditions are met: absolute neutrophil count ≥ 1.5 x 109/l; thrombocyte count ≥ 100 x 109/l; CTC non-haematological toxicity ≤ Grade 1 (except for alopecia, nausea, vomiting).
a: Behandling med konkomitant TMZ kan fortsættes, når alle de følgende betingelser er opfyldt: Absolut antal neutrofile ≥ 1,5 x 109/l; trombocyttal ≥ 100 x 109/l; CTC ikke-hæmatologisk toksicitet ≤ Grad 1 (undtaget alopeci, kvalme, opkastning).
a: Treatment with concomitant TMZ can be continued when all of the following conditions are met: absolute neutrophil count ≥ 1.5 x 109/l; thrombocyte count ≥ 100 x 109/l; CTC non-haematological toxicity ≤ Grade 1 (except for alopecia, nausea, vomiting).
a: Behandling med konkomitant TMZ kan fortsættes, når alle de følgende betingelser er opfyldt: Absolut antal neutrofile  1,5 x 109/l; trombocyttal  100 x 109/l; CTC ikke-hæmatologisk toksicitet  Grad 1 (undtagen for alopeci, kvalme, opkastning).
a: Treatment with concomitant TMZ can be continued when all of the following conditions are met: absolute neutrophil count  1.5 x 109/l; thrombocyte count  100 x 109/l; CTC non-haematological toxicity  Grade 1 (except for alopecia, nausea, vomiting).
a: Behandling med TMZ i kombination kan fortsættes, når alle de følgende betingelser er opfyldt: Absolut antal neutrofile ≥ 1,5 x 109/l; trombocyttal ≥ 100 x 109/l; CTC ikke-hæmatologisk toksicitet ≤ Grad 1 (undtaget alopeci, kvalme, opkastning).
a: Treatment with concomitant TMZ can be continued when all of the following conditions are met: absolute neutrophil count ≥ 1.5 x 109/l; thrombocyte count ≥ 100 x 109/l; CTC non-haematological toxicity ≤ Grade 1 (except for alopecia, nausea, vomiting).
A: Blanding af det anviste antal breve REYATAZ oralt pulver sammen med modermælkserstatning i en lille medicinkop eller lille beholder og indgivelse med en mundsprøjte, som fås på apoteket:
A: To mix the recommended number of REYATAZ oral powder sachets with liquid infant formula in a small medicine cup or small container and to administer with an oral syringe, which can be obtained from a pharmacist:
a: Der foreligger kun begrænsede data for doser under 8 mg.
a Limited data are available for doses below 8 mg
A: doxorubicin; C: cyclophosphamid; P: paclitaxel; D: docetaxel; Carb: carboplatin; H: trastuzumab
A: doxorubicin; C: cyclophosphamide; P: paclitaxel; D: docetaxel; Carb: carboplatin; H: trastuzumab CI = confidence interval
a: Identificeret i det kliniske forsøg b: Identificeret ved erfaring efter markedsføring c: Identificeret ved erfaring efter markedsføring, og erfaring fra sundhedspersonale i forbindelse med utilsigtet eksponering. d: Data fra sikkerhedsovervågning efter markedsføring (PMSS), symptomer associeret med akut seponering af lægemidlet og/eller fejl i tilførselssystemet.
a: Identified from the clinical trial b: Identified from Post Marketing experience c: Identified from Post-Marketing experience, experienced by healthcare personnel following accidental exposure d: Post Marketing Safety Surveillance (PMSS) data, effects associated with acute withdrawal of the medicinal product, and /or delivery system failures.
a: Identificeret i det kliniske forsøg b: Identificeret ved erfaring efter markedsføring c: Identificeret ved erfaring efter markedsføring, og erfaring fra sundhedspersonale i forbindelse med utilsigtet eksponering. d: Data fra sikkerhedsovervågning efter markedsføring (PMSS), symptomer associeret med akut seponering af lægemidlet og/eller fejl i tilførselssystemet.
a: Identified from the clinical trial b: Identified from Post-Marketing experience c: Identified from Post-Marketing experience, experienced by healthcare personnel following accidental exposure d: Post Marketing Safety Surveillance (PMSS) data, effects associated with acute withdrawal of the medicinal product, and /or delivery system failures.
a: Negativ ændring i scoren indikerer forbedring. b: Kun patienter, der har både en baseline-værdi og mindst én værdi efter baseline, var inkluderet.
a: Negative change in score indicates improvement. b: Only patients having both baseline and at least one post baseline were included.
A: p < 0,001, Enbrel vs. placebo
a: p <0.001, Enbrel vs. placebo
a: p < 0,001, Enbrel vs. placebo
a: p<0.001, Enbrel vs. placebo
a: Patienter, som ikke gennemførte 12 måneder af studiet, b lev betragtet som ikke- responderende. b: Værdier for sygdoms aktivitets score (Disease Activity Score, DAS) er middelværdier. c: remission er defineret som DAS<1,6
a: Patients who did not complete 12 months in the study were considered to be non-responders. b: Values for Disease Activity Score (DAS) are means. c: Remission is defined as DAS <1.6.
a: Patienter, som ikke gennemførte 12 måneder af studiet, blev betragtet som ikke- responderende. b: Værdier for sygdoms aktivitets score (Disease Activity Score, DAS) er middelværdier. c: remission er defineret som DAS<1,6
a: Patients who did not complete 12 months in the study were considered to be non-responders. b: Values for Disease Activity Score (DAS) are means. c: Remission is defined as DAS <1.6
a: Patienter, som ikke gennemførte 12 måneder af studiet, blev betragtet som ikke- responderende. b: Værdier for sygdoms aktivitets score (Disease Activity Score, DAS) er middelværdier. c: remission er defineret som DAS<1,6
a: Patients who did not complete 12 months in the study were considered to be non-responders. b: Values for Disease Activity Score (DAS) are means. c: Remission is defined as DAS <1.6.
a: Patienter, som ikke gennemførte 12 måneder af studiet, blev betragtet som ikke- responderende. b: Værdier for sygdoms aktivitets score (Disease Activity Score, DAS) er middelværdier. c: Remission er definert som DAS<1,6
a: Patients who did not complete 12 months in the study were considered to be non- responders. b: Values for Disease Activity Score (DAS) are means. c: Remission is defined as DAS <1.6.
a: Patienter, som ikke gennemførte 12 måneder af studiet, blev betragtet som ikke- responderende. b: Værdier for sygdoms aktivitets score (Disease Activity Score, DAS) er middelværdier. c: Remission er definert som DAS<1,6
a: Patients who did not complete 12 months in the study were considered to be non-responders. b: Values for Disease Activity Score (DAS) are means. c: Remission is defined as DAS <1.6.
a: Pearsons chi-square-test af forskel mellem placebo og eptifibatid.
a: Pearson’s chi-square test of difference between placebo and eptifibatide.
a: Pearsons chi-square-test af forskellen mellem placebo og eptifibatid.
a: Pearson’s chi-square test of difference between placebo and eptifibatide.
a: Pearson’s chi-square test af difference mellem placebo og eptifibatid.
a: Pearson’s chi-square test of difference between placebo and eptifibatide.
a: Respons på behandling blev defineret som ikke detekterbar hcv-RNA 24 uger efter behandlingen, laveste grænse for detektion = 125 IE/ml.
a: Response to treatment was defined as undetectable HCV-RNA at 24 weeks post-treatment lower limit of detection=125IU/ml
a: TMZ-dosisniveau er anført i Tabel 2. b: TMZ skal seponeres, hvis:
a: TMZ dose levels are listed in Table 2. b: TMZ is to be discontinued if:
a: TMZ-dosistrin er anført i tabel 2. b: TMZ skal seponeres, hvis:
a: TMZ dose levels are listed in Table 2. b: TMZ is to be discontinued if:
a: Two-tailed log rank test med sammenligning af overlevelseskurverne mellem behandlingsgrupperne. b: Two-tailed kontinuitetskorrigeret chi i anden test.
a: Two-tailed log rank test comparing survival curves between treatment groups. b: Two-tailed continuity-corrected chi-square test.
a: Yderligere dosisreduktioner bør overvejes på en individuel patientbasis, da der foreligger begrænsede data for doser under 10 mg.
a: Further dose reductions should be considered on an individual patient basis as limited data are available for doses below 10 mg.
AADMINISTRATIONSMETODE
METHOD OF ADMINISTRATION
aAlle analyser af kliniske endepunkter var intent-to-treat; bMR-kohorte anvendtt ved MR-analyser
aAll analyses of clinical endpoints were intent-to-treat; bMRI analysis used MRI cohort
aAnalysen omfatter studier med knoglemarvstransplantationer i denne periode; i nogle studier blev GM-CSF (granulocykolonistimulerende faktor) anvendt. bAnalysen omfatter patienter, der fik knoglemarvstransplantater i denne periode.
aAnalysis includes studies involving bone marrow transplant during this period; some studies used GM-CSF (granulocyte-macrophage–colony stimulating factor) bAnalysis includes patients receiving bone marrow transplant during this period
aANC<0,5 x 109/l
aANC < 0.5 x 109/l
aANC<0,5 x 109/l og/eller
aANC <0.5x109/1
aAndet inkluderer skulder, ryg, ben.
aOther includes shoulder, back, leg.
Aangezien er geen klinische gegevens voorhanden zijn over gevallen van gebruik van clopidogrel tijdens de zwangerschap, is het als voorzorgsmaatregel beter om tijdens de zwangerschap geen clopidogrel te gebruiken.
As no clinical data on exposure to clopidogrel during pregnancy are available, it is preferable not to use clopidogrel during pregnancy as a precautionary measure.
Aangezien hogere doses ASA geassocieerd zijn met een hoger risico op bloedingen, is het aanbevolen geen hogere dosis ASA te nemen dan 100 mg.
Since higher doses of ASA were associated with higher bleeding risk it is recommended that the dose of ASA should not be higher than 100 mg.
Aanæmi, leukopeni, hæmolyse (herunder hæmolytisk anæmi, anisocytose (herunder mikrocytose.
Anaemia, leukopenia, haemolysis (including haemolytic anaemia), anisocytosis (including microcytosis)
Aard en inhoud van de verpakking
Nature and contents of container
AAV1-LPLS447X blev administreret til 8 LPLD-patienter i en 12 ugers åben dosiseskaleringsstudie (1 × 1011 gc til 3 × 1011 gc pr. kg legemsvægt i.m.).
AAV1-LPLS447X was administered to 8 LPLD patients in a 12-week, open label dose escalating study (1 x 1011 gc to 3 x 1011 gc per kg body weight i.m.).
Abacavir
Psychiatric disorders
abacavir
↔ abacavir
Abacavir (600 mg én gang dagligt)
Abacavir (600 mg once daily)
Abacavir 300 mg x 2 (TPV/r 750/100 mg x 2)
Abacavir 300 mg BID
Abacavir beholder den antiretrovirale aktivitet over for lamivudin-resistent hiv-1, der kun har M184V-mutationen.
Abacavir maintains its antiretroviral activities against lamivudine- resistant HIV-1 harbouring only the M184V mutation.
Abacavir beholder den antiretrovirale aktivitet over for lamivudin-resistente hiv-1, der kun har M184V mutationen.
Abacavir maintains its antiretroviral activities against lamivudine- resistant HIV-1 harbouring only the M184V mutation.
Abacavir beholder den antiretrovirale aktivitet over for lamivudin-resistente hiv-1, der kun har M184V-mutationen.
Abacavir maintains its antiretroviral activities against lamivudine- resistant HIV-1 harbouring only the M184V mutation.
Abacavir beholder den antiretrovirale aktivitet overfor lamivudin-resistent hiv-1, der kun har M184V-mutationen.
Abacavir maintains its antiretroviral activities against lamivudine- resistant HIV-1 harbouring only the M184V mutation.
Abacavir bliver metaboliseret intracellulært til den aktive del, carbovir 5’- triphosphat (TP).
Abacavir is metabolised intracellularly to the active moiety, carbovir 5’- triphosphate (TP).
Abacavir Cmax ↓ 46% Abacavir AUC ↓ 36%
Abacavir Cmax ↓ 46
Abacavir hæmmer ikke CYP- isoformer i humane levermikrosomer.
In human liver microsomes, abacavir did not inhibit cytochrome P450 isoforms.
Abacavir hæmmer ikke CYP-isoformer i humane levermikrosomer.
In human liver microsomes, abacavir
Abacavir Lamivudin Zidovudin
Abacavir Lamivudine
Abacavir metaboliseres primært i leveren.
Abacavir is primarily metabolised by the liver.
Abacavir må ikke anvendes til patienter, der bærer HLA-B*5701-allel.
Abacavir should not be used in patients known to carry the HLA-B*5701 allele
Abacavir og lamivudin hverken hæmmer eller inducerer CYP-enzymer (f.eks.
Abacavir and lamivudine do not inhibit or induce CYP enzymes (such as CYP 3A4, CYP 2C9 or CYP 2D6).
Abacavir og lamivudin metaboliseres ikke signifikant af CYP-enzymer.
Abacavir and lamivudine are not significantly metabolised by CYP enzymes.
Abacavir og lamivudin tilhører en gruppe af antiretrovirale lægemidler, der kaldes nukleosidanalog revers transkriptase-hæmmere (NRTI’er), og dolutegravir tilhører en gruppe af antiretrovirale lægemidler, der kaldes integrasehæmmere (INI'er).
Abacavir and lamivudine belong to a group of anti-retroviral medicines called nucleoside analogue reverse transcriptase inhibitors (NRTIs), and dolutegravir belongs to a group of anti-retroviral medicines called integrase inhibitors (INIs).
Abacavir og zidovudine
Abacavir and zidovudine
abacavir zidovudin
abacavir zidovudine
abacavir, efavirenz, tenofovirdisoproxilfumarat, zidovudin
abacavir, efavirenz, tenofovir disoproxil fumarate, zidovudine
Abacavir, zidovudin: Koncentrationerne kan være nedsat på grund af øget glucuronidering af Kaletra..
Abacavir, Zidovudine: Concentrations may be reduced due to increased glucuronidation by Kaletra.
Abacavir-resistente isolater af hiv-1 er blevet selekteret in vitro og in vivo og er forbundet med specifikke genotypiske ændringer i RT-codonregionen (codon M184V, K65R, L74V og Y115F).
Abacavir-resistant isolates of HIV-1 have been selected in vitro and in vivo and are associated with specific genotypic changes in the RT codon region (codons M184V, K65R, L74V and Y115F).
Abacavir/
Abacavir/ lamivudine
Abacavir/ lamivudin
Abacavir/ lamivudine
Abacavir: AUC  41 %
Abacavir: AUC  41
Abacavir: AUC  41 % Ethanol: AUC 
Abacavir: AUC 41% Ethanol: AUC 
Abacavir: AUC, Cmin og Cmax for abacavir var uændrede, når det blev givet med amprenavir.
Abacavir: the AUC, Cmin, and Cmax of abacavir were unaltered when given with amprenavir.
Abacavirs antivirale aktivitet i cellekulturer blev ikke antagoniseret ved kombination med nukleosid revers transkriptasehæmmere (NRTI’er) didanosin, emtricitabin, stavudin eller tenofovir, non-nukleosid revers transkriptasehæmmeren (NNRTI) nevirapin eller proteasehæmmeren (PI) amprenavir.
The antiviral activity of abacavir in cell culture was not antagonized when combined with the nucleoside reverse transcriptase inhibitors (NRTIs) didanosine, emtricitabine, stavudine or tenofovir, the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine, or the protease inhibitor (PI) amprenavir.
Abacavirs farmakokinetik er blevet undersøgt hos patienter med let nedsat leverfunktion (Child-Pugh score 5-6), der fik en enkelt dosis på 600 mg; den mediane (interval) AUC var 24,1 (10,4 - 54,8) mikrog∙time/ml.
The pharmacokinetics of abacavir have been studied in patients with mild hepatic impairment (Child-Pugh score 5-6) receiving a single 600 mg dose; the median (range) AUC value was 24.1 (10.4 to 54.8) ug.h/ml.
Abacavirs farmakokinetik er blevet undersøgt hos patienter med let nedsat leverfunktion (Child-Pugh score 5-6), der fik en enkelt dosis på 600 mg; den mediane (interval) AUC var 24,1 (10,4 - 54,8) mikrog∙time/ml.
The pharmacokinetics of abacavir have been studied in patients with mild hepatic impairment (Child-Pugh score 5-6) receiving a single 600 mg dose; the median (range) AUC values was 24.1 (10.4 to 54.8) ug.h/ml.
ABASAGLAR 100 enheder/ ml injektionsvæske, opløsning i cylinderampul er en klar og farveløs opløsning.
ABASAGLAR 100 units/mL solution for injection in a cartridge is a clear and colourless solution.
ABASAGLAR 100 enheder/ ml injektionsvæske, opløsning i fyldt pen, KwikPen, er en klar og farveløs opløsning.
ABASAGLAR 100 units/mL solution for injection in a pre-filled pen, KwikPen, is a clear and colourless solution.
ABASAGLAR 100 enheder/ml injektionsvæske, opløsning i cylinderampul Eli Lilly Italia S.p.A.,
ABASAGLAR 100 units/mL solution for injection in a cartridge Eli Lilly Italia S.p.A.,
ABASAGLAR 100 enheder/ml injektionsvæske, opløsning i cylinderampul Insulin glargin
ABASAGLAR 100 units/mL solution for injection in a cartridge Insulin glargine
ABASAGLAR 100 enheder/ml injektionsvæske, opløsning i fyldt pen Insulin glargin
ABASAGLAR 100 units/mL solution for injection in a pre-filled pen Insulin glargine
ABASAGLAR 100 enheder/ml injektionsvæske, opløsning, i cylinderampul
ABASAGLAR 100 units/mL solution for injection in a cartridge
ABASAGLAR 100 enheder/ml injektionsvæske, opløsning, i en fyldt pen Insulin glargin
ABASAGLAR 100 units/mL solution for injection in a pre-filled pen Insulin glargine
ABASAGLAR 100 enheder/ml injektionsvæske, opløsning, i fyldt pen
ABASAGLAR 100 units/mL solution for injection in a pre-filled pen
ABASAGLAR 100 enheder/ml, injektionsvæske, opløsning KwikPen
ABASAGLAR 100 U/mL injection KwikPen